CALL - SPRINTER OPEN END - GILEAD SCIENCES | Market Closed - Börse Stuttgart 20:38:22 10/05/2024 BST | ||
| 1.03 EUR | +14.44% |
|
| Current month | +7.29% | ||
| 1 month | -19.53% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/05/24 | 1.03 | +14.44% | 0 |
| 09/05/24 | 0.9 | -3.23% | 0 |
| 08/05/24 | 0.93 | -8.82% | 0 |
| 07/05/24 | 1.02 | +6.25% | 0 |
| 06/05/24 | 0.96 | +5.49% | 0 |
Delayed Quote Börse Stuttgart
Last update May 10, 2024 at 08:38 pm
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | 
Vontobel
|
| WKN | VN9Z85 |
| ISIN | DE000VN9Z858 |
| Date issued | 17/12/2018 |
| Strike | 55.21 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.43 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.59 € |
|---|---|
| Lowest since issue | 0.51 € |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
65.96
USD
Average target price
82.93
USD
Spread / Average Target
+25.73%
- Stock Market
- Certificates
- Certificat
